A Phase 1b, Open-label, Partially Randomised Study to Assess Safety and Compare Pharmacokinetics of New Oral hPTH(1-34) Tablet Formulations vs. Oral EBP05 Tablets and Subcutaneous Forteo Injection in Healthy Male Subjects
Latest Information Update: 14 Apr 2025
At a glance
- Drugs Teriparatide (Primary) ; Teriparatide
- Indications Hypoparathyroidism; Osteoporosis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Entera Bio
Most Recent Events
- 09 Apr 2025 Planned End Date changed from 1 May 2025 to 1 May 2026.
- 09 Apr 2025 Planned primary completion date changed from 1 May 2025 to 1 May 2026.
- 04 Nov 2024 Planned End Date changed from 1 Mar 2025 to 1 May 2025.